Indaptus Therapeutics Stock Fundamentals
| INDP Stock | USD 1.03 0.01 0.96% |
Indaptus Therapeutics fundamentals help investors to digest information that contributes to Indaptus Therapeutics' financial success or failures. It also enables traders to predict the movement of Indaptus Stock. The fundamental analysis module provides a way to measure Indaptus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Indaptus Therapeutics stock.
At this time, Indaptus Therapeutics' Interest Expense is relatively stable compared to the past year. As of 11/28/2024, Total Other Income Expense Net is likely to grow to about 1 M, while Gross Profit is likely to drop (1.3 K). Indaptus | Select Account or Indicator |
Indaptus Therapeutics Company Current Valuation Analysis
Indaptus Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Indaptus Therapeutics Current Valuation | 3.23 M |
Most of Indaptus Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Indaptus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Indaptus Therapeutics has a Current Valuation of 3.23 M. This is 99.98% lower than that of the Biotechnology sector and 99.93% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Indaptus Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Indaptus Therapeutics's current stock value. Our valuation model uses many indicators to compare Indaptus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Indaptus Therapeutics competition to find correlations between indicators driving Indaptus Therapeutics's intrinsic value. More Info.Indaptus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Indaptus Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Indaptus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Indaptus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indaptus Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics of similar companies.Indaptus Therapeutics is currently under evaluation in current valuation category among its peers.
Indaptus Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 3.23 M | ||||
| Shares Outstanding | 10.2 M | ||||
| Shares Owned By Insiders | 26.67 % | ||||
| Shares Owned By Institutions | 5.99 % | ||||
| Number Of Shares Shorted | 84.95 K | ||||
| Price To Book | 1.75 X | ||||
| EBITDA | (16.38 M) | ||||
| Net Income | (15.42 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 175.05 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | (13.41 M) | ||||
| Short Ratio | 0.54 X | ||||
| Earnings Per Share | (1.70) X | ||||
| Target Price | 8.5 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 10.5 M | ||||
| Total Asset | 14.92 M | ||||
| Retained Earnings | (45.42 M) | ||||
| Working Capital | 11.22 M | ||||
| Net Asset | 14.92 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 1.3 K | 1.2 K |
Pair Trading with Indaptus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Indaptus Stock
| 0.78 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Indaptus Stock
| 0.67 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.46 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.44 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.